Trial design for next generation PrEP

HIV Forum

The extremely high efficacy of current PrEP raises new challenges for next-generation PrEP.

Placebo-controlled studies are seen as unethical, now that oral PrEP should be standard of care prevention. It is also impractical to use randomised studies with active controls: whether for non-inferiority or superiority endpoints, the studies would need to be too large.

This satellite session organised by the HIV Forum discussed new approaches that are already being used in phase 3 PrEP studies using longer-acting drugs like islatravir and lenacapavir. The webcast is now online.


Innovative clinical trial designs to accelerate increase in PrEP choices. IAS 2021 satellite session. 18 July 2021.

Links to other websites are current at date of posting but not maintained.